Chronic heart failure (CHF) is associated with endothelial dysfunction. Activation of the reninangiotensin-aldosterone system (RAAS) is believed to be important in the deterioration of endothelial dysfunction in CHF through stimulation of oxidative stress. Whereas angiotensin-converting enzyme inhibitors (ACE-I) improve endothelial function in CHF, the effects of angiotensin II AT 1 -receptor blockers (ARB) are less well established. Therefore we compared the effects of the ACE-I lisinopril vs. the ARB candesartan on endothelial dysfunction in a rat model of CHF.
Introduction
Experimentally, in animal models of chronic heart failure (CHF), [1] [2] [3] as well as clinically in heart failure patients, 4, 5 endothelial dysfunction has been identified as the impaired dilatory response to acetylcholine in a setting of preserved responsiveness to vasodilators such as nitroprusside. This endothelial dysfunction, leading to abnormal vasomotor control, may give rise to increased peripheral vascular resistance, a hallmark of CHF. As such, endothelial dysfunction is regarded to be one of the underlying and contributing factors for the progressive nature of CHF. 5 Consequently, prevention or reversal of endothelial dysfunction may be considered an important target for pharmacological intervention in CHF.
The chronically activated (tissue) reninangiotensin-aldosterone system (RAAS) is believed to contribute significantly to the deterioration of cardiovascular function, 6, 7 including in CHF. Angiotensin II (Ang II), the effector molecule of the RAAS, has shown to be an important stimulus for increased oxidative stress through vascular superoxide production via membrane NADH/ NADPH oxidase activation. 8 Hence, reactive oxygen radicals may contribute to endothelial dysfunction through inactivation of endotheliumderived nitric oxide (NO). 9 Recent experimental findings suggest that heart failure is associated with increased oxidative stress, and that this may underlie endothelial dysfunction in CHF through increased vascular superoxide production. 10 Ang II is formed from angiotensin I (Ang I) by the action of angiotensin-converting enzyme (ACE) and other enzymes and exerts its effect through stimulation of the angiotensin II type 1 (AT 1 )-receptor. 11 Using the rat coronary ligation/myocardial infarction (MI) model of CHF, several investigators have reported that interruption of the RAAS through chronic ACE inhibition improves/restores the response to acetylcholine. 2, 3, 12 This is in line with the idea that the Ang II-mediated increase in oxidative stress, which underlies the impaired NOactivity in endothelial dysfunction associated with CHF, is counteracted by ACE-I through prevention of Ang II formation. If true, one would predict that similar effects might be obtained by blockade of the AT 1 -receptor. In support of this are reports describing comparable beneficial effects of ACE inhibition and AT 1 -receptor antagonism on parameters such as left ventricular ejection fraction, interstitial collagen fraction, myocardial hypertrophy and survival. [13] [14] [15] However, similarities/discrepancies of chronic treatment with an ACE-I compared with an AT 1 -receptor blocker (ARB), regarding their effects on endothelial dysfunction in CHF, have been less well established.
To address this issue, therefore, rats with experimentally-induced MI-induced heart failure were compared for improvement of aortic endothelial dysfunction after treatment with either the ACE-I lisinopril, or the ARB, candesartan cilexetil. Endothelial function was assessed as the dilatory response to acetylcholine (ACh) and the nitric oxide synthase (NOS-) inhibitor N G -monomethyl-L-arginine (L-NMMA) was used to determine the contribution of NO in the response.
Methods

Myocardial infarction model
All procedures were reviewed and approved by the Animal Research Committee at the University of Groningen. Normotensive male Wistar rats (250-300 g; Harlan, Zeist, The Netherlands) were housed group-wise at the Central Animal Laboratory, University of Groningen (The Netherlands). They had free access to food and water. At the time of the operation, anaesthesia was induced with isoflurane (2.0-2.5% in oxygen), after which rats were intubated and mechanically ventilated with this gas-mixture (Amsterdam Infant Ventilator, Hook/Loos, Schiedam, The Netherlands). MI was induced by direct coronary ligation as described before. 16 Briefly, a left-sided thoracotomy was performed and the anterior descending coronary artery occluded with a 6-0 silk suture 1-2 mm after the bifurcation. Care was given to obtain a blanching of the ligature to confirm MI. If necessary the procedure was repeated by placement of a second or third ligature. Thereafter, the thorax was closed and as soon as spontaneous respiration was sufficient, the rats were extubated and were allowed to recover under a heated lamp.
Stratification and treatment
One week after surgical procedures, surviving rats were anaesthetised and subjected to ECG-measurements, based on which individual rats with ECGevidence of MI (averaged QT-interval prolongation in three pre-cordial leads) were assigned to treatment with lisinopril, candesartan, or no-treatment. Rats with minor or no ECG-evidence of MI were additionally allocated to a no-treatment regimen to function as a control group, giving rise to four experimental groups in total. As described previously, 17 ECG-stratification was used for a balanced distribution of rats with different MI-size over the experimental MI-groups only and, in all cases, group stratification was checked at post-mortem by quantitative left ventricular histopathology.
Rats allocated to one of the two active treatment regimens received either lisinopril or candesartan cilexetil mixed with the chow (Hope Farms, Woerden, The Netherlands). The remaining rats served as non-treated controls. Based on drug analysis of the food (Dr P Morsing, AstraZeneca, Mölndal, Sweden), together with the assessment of food-intake and body weight, the average daily dose of lisinopril and candesartan cilexetil was approximately 2 mg/kg and 1.5 mg/kg, respectively. To avoid a potential effect of early pharmacological intervention on infarct-size and wound healing, 3, 18 treatment was started two weeks after induction of MI (i.e., established MI). Treatment lasted for 11-12 weeks and animals were sacrificed at 13-14 weeks after initial surgical procedures.
Sacrifice
The rats were anaesthetised with isoflurane in 2% oxygen. The right carotid artery was catheterised with a polyethylene catheter filled with 0.9% saline with heparin (5000 U/L). The carotid catheter was advanced into the aorta for recording of the aortic blood pressure (Stratham 23 Db, Gould Instruments, Cleveland, Ohio, USA).
Subsequently, heparin (5000 IU kg -1 ) was administered via the tail vein. The hearts were excised and rapidly arrested in ice-cold NaCl, and mounted in an organ perfusion set-up. Retrograde perfusion of the aorta at 38°C, essentially by the Langendorff method, was achieved immediately. The hearts started to beat spontaneously and, after equilibration for 10 minutes, baseline measurements were performed on LV pressure, contractility, relaxation, heart rate and coronary flow, as described in detail elsewhere. 16, 19 Thereafter, hearts were arrested in diastole in KCl (2 mol/L) and weighed. To determine the infarct size, the scar-tototal LV circumference ratio was measured as described in detail elsewhere. 18 Rats that were assigned to one of the MI-groups, but which appeared to have an infarct-size <20%, were excluded from analysis.
After excision of the heart, the thoracic descending aorta was removed and placed in a buffer solution (Krebs) of the following composition (mM): NaCl (120.4), KCl (5.9), CaCl 2 (2.5), MgCl 2 (1.2), NaH 2 PO 4 (1.2), glucose (11.5), and NaHCO 3 (25.0).
Organ bath studies with isolated aortic rings
The aorta was cleaned of adhering tissue and rings of 2 mm in length were cut with a sharp razor blade. Rings were then mounted in an organ bath containing Krebs buffer at 37°C, aerated with 95% O 2 /5% CO 2 , and indomethacin (10 µM) to avoid the potential interference of vasoactive prostanoids. Rings were connected to an isotonic displacement transducer at a preload of 14 mN and were allowed to equilibrate for at least 60 minutes, during which regular washing periods were performed. 20 Rings were then checked for viability by repeated stimulation with 1 µM phenylephrine (PE).
After washing and restabilisation, one subset of rings was precontracted with 1 µM PE. The response to increasing doses of the endotheliumdependent vasodilator ACh (10 nM to 10 µM), in the presence or absence of the NO-synthase inhibitor L-NMMA (100 µM), and to the endothelium-independent dilator nitroglycerin (NTG, 1 nM to 10 µM), in the absence of L-NMMA only, was determined. In another set of rings, the contractile response to increasing concentrations of Ang II (0.1 nM to 1 µM) was measured in the presence of L-NMMA. 21 Subsequently, these rings were contracted to their maximum by a bolus of PE (1 µM).
Calculations and statistical analysis
Vasodilator responses to ACh and NTG and constrictor responses to Ang II were expressed as a percentage of PE-induced pre-and post-contraction, respectively, before individual concentrationresponse curves were generated and the Area Under each individual Curve (AUC) was determined (SigmaPlot scientific graphing software package, Jandell Scientific). The AUC was used to 
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represent the individual response-size to a given agonist in a given condition and, where appropriate, to calculate the difference in response-size between different conditions (i.e., difference in response-size in the presence of indomethacin vs. indomethacin plus L-NMMA for ACh). In this way, employing the AUC provided us with a simple (and straightforward) method for estimation and analysis of the L-NMMA-sensitive (hence, NO-mediated) and -resistant (hence, endothelium-derived hyperpolarising factor [EDHF]/other-mediated) part of the response to ACh. For reasons of consistency, the AUC was also used to calculate and present the average response-size for each group, as well as for subsequent analysis of differences between groups.
Unless stated otherwise, all data are expressed as mean±SEM. The four experimental groups were compared using one-way analysis of variance (ANOVA), in combination with Dunnet post-hoc analysis for multiple comparison, using non-MI as the control category (SPSS for windows Standard Version 8.0). In addition, MI-groups were compared using ANOVA, in combination with Dunnet post-hoc analysis, using untreated MI as the control category. Differences were considered significant at a level of p<0.05.
Results
Rats that survived all surgical procedures, had an infarct-size >20% in the case of MI-groups, and which successfully underwent all experimental studies were included for analysis. Final groupsizes, based upon which the results are presented, are n=8 for no-MI, n=11 for MI, n=8 for lisinopril and n=6 for candesartan.
Rat characteristics
Mean infarct-size was evenly balanced between the three experimental MI-groups, and the rats in these groups all showed clear evidence of left ventricular (LV) dysfunction, compared with rats with no MI (Table 1) .We have previously shown that LV pressure and dP/dT (i.e., contractility and relaxation) are significantly decreased and become progressively attenuated in rats with MI-induced heart failure. 16 Concurrent haemodynamic abnormalities in this MI-model of heart failure are related to increased cardiac weight and infarct-size. 22, 23 In the present study, untreated MI-rats, displaying an infarct-size of 34% on average, were characterised by LV-dysfunction and increased heart and lung weights (Table 1 ). In addition, baseline coronary flow, which is co-determined by intact coronary endothelial function, was significantly decreased in untreated MI. In contrast, lisinopril and candesartan prevented the increase in heart and lung weight, suggesting that both treatment regimens effectively prevented the progression of LV-dysfunction to CHF. Moreover, baseline coronary flow was significantly larger after lisinopril and candesartan, suggesting that coronary endothelial function was preserved after both treatments.
Ang II-induced vasoconstriction
In the present study, Ang II-induced vasoconstriction, presented as AUC, (Figure 1 ; see also methods) was significantly increased by lisinopril, as compared with no-treatment, while after candesartan it was virtually abolished.The differences in the AUC were a result of alterations in the maximum response to Ang II, rather than a parallel shift of the concentration-response curve (data not shown).We have previously shown that effective (biochemically assessed) inhibition of vascular ACE after chronic oral ACE-I results in an increased response to Ang II, possibly due to AT 1 -receptor upregulation, in isolated rings in vitro. 21 Taken together, these data may provide functional evidence for effective RAAS-inhibition at the vascular level after chronic oral lisinopril and candesartan.
ACh-induced vasodilation
In the present study, the response-size of ACh was markedly impaired in the group of untreated MIrats at 13 weeks post-MI (-50% on average), as compared with those with no-MI (Figure 2 ). The decrease of the AUC in the MI-rats was due to a decrease in the maximum response to ACh rather than differences in sensitivity to ACh (data not PAPER shown). This is consistent with previous studies suggesting progressive endothelial dysfunction in this MI-model, first detectable in the aorta as the impaired response to ACh at approximately eight weeks post-MI. [1] [2] [3] 12 Inhibition of NOS, using L-NMMA, significantly reduced the response to ACh (p<0.001, Figure 2 ) in the present study, indicating the involvement of NO. However, the L-NMMA-sensitive part of the dilator response was significantly smaller in untreated MI-rats (-49% on average), indicating a decreased NO-contribution compared with control rats with no-MI. Moreover, the part of the response to ACh which was resistant to L-NMMA (and indomethacin) was also significantly decreased in untreated MI (-49% on average), pointing to a decreased contribution of a nonprostanoid/non-NO vasodilator substance as well. Treatment with lisinopril and candesartan both fully restored the response the ACh, including the part mediated by NO.
NTG-induced vasodilation
The intact endothelium-independent response to NTG rules out a potential impairment at the level of vascular smooth muscle reactivity to NO which might have accounted for the attenuated response to ACh in untreated MI (Figure 3) . Furthermore, lisinopril and candesartan did not significantly alter the response to NTG, thereby excluding the possibility that their beneficial effects on AChinduced dilatation were, in fact, due to increased reactivity to exogenous NO.
Discussion
We compared the vasoprotective effect of the ACE-I, lisinopril, vs. the ARB, candesartan, on endothelial function in a rat model of experimental CHF. We found that candesartan and lisinopril normalised endothelial function in a similar fashion.
Endothelial function in the present study was assessed by the vasodilatory response to ACh in isolated aortic segments. Several endotheliumderived substances may be involved in this response, including NO, vasoactive prostanoids, and EDHF.
Stimulation of endothelial cells with ACh leads to increased intracellular calcium concentrations, with many results, including activation of NO synthase (NOS) and stimulation of NO-production. 24 Recent findings suggest a marked downregulation of the NO-contribution to ACh-induced dilation in the rat MI model of CHF. 25 This attenuated contribution might be caused by decreased NO-forma- 
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PAPER tion, resulting from changes at the level of the receptor for ACh and/or at the level of the signalling pathway leading to impaired NOS-activation. On the other hand, increased NO-breakdown by stimulation of NO-inactivating pathways might also be involved. Oxygen radicals, such as superoxide (O 2 -), can inactivate NO. 9 Superoxide, produced by aortic NADPH, is reported to impair the ACh-induced vasodilation in the rat MI model of CHF. 10 Other studies have confirmed the relationship between oxidative stress and CHF. 9 Indeed, superoxide dismutase was able to restore the impaired ACh-mediated vasodilation in CHF rats. 10 CHF is associated with an activated RAAS in this model, as well as in humans. 16 Ang II, the effector molecule of the RAAS, is able to induce the production of superoxide, leading to increased oxidative stress. In addition, ACE, the enzyme responsible for conversion of Ang I to Ang II, facilitates the breakdown of bradykinin, a potent vasodilator and anti-ischaemic substance. 26 Thus, blockade of the RAAS is expected to be an effective pharmacological option. Indeed, ACE-I and ARBs have been proven to be effective treatments in preventing signs of left ventricular dysfunction and heart failure in the rat model and in humans. [13] [14] [15] [27] [28] [29] [30] [31] Moreover,ACE inhibition has been shown to be able to normalise the response to ACh in heart failure. 2, 3, 12 The effect of blockade of the AT 1 -receptor by an ARB on endothelial function is less well established. Since ARBs inhibit the effects of Ang II by blocking the AT 1 -receptor, they exert their effect by only attenuating the processes induced by Ang II, such as increased oxidative stress. Unlike ACE inhibition, therefore, Ang II receptor blockade will not lead to increased availability of bradykinin.
In our study, the attenuation of the vasodilator response to ACh in rats with untreated chronic heart failure could be fully restored by chronic RAAS-blockade. Moreover, ACE inhibition (lisinopril) and AT 1 -receptor blockade (candesartan) were equally effective.This might indicate that the effects of ACE inhibition on rats with CHF are mediated mainly by diminishing the conversion of Ang I to Ang II, and not so much by increasing the availability of bradykinin.
The attenuation of the vasodilator response to ACh is, in part, due to decreased NO-activity in the aortic wall, since the L-NMMA-sensitive part of the vasodilation was decreased in the MI-group. Treatment with lisinopril, as well as with candesartan, increased the NO-dependent vasodilation to the level of the rats with no MI.These results ground the idea that the improvement of endothelial function by lisinopril and by candesartan is, in part, due to decrease of Ang II-induced oxidative stress.
Previous studies showed the limited role of vasoactive prostanoids in the aortic response to ACh in normal rats, as well as in rats with heart failure. 1, 32 In our study design, the rat aortae were incubated with indomethacin to fully exclude the possible influence of prostanoids on the endothelium.
Despite the presence of LNMMA and indomethacin, the aorta was still able to dilate in response to ACh.This part of the vasodilation was also attenuated in the non-treated MI-group, and both lisinopril and candesartan restored this part of the dilator response to the level of the no-MI group. EDHF is the most likely candidate for this non-NO, non-prostanoid-mediated vasodilation, but we cannot fully establish the nature of this, since we did not collect evidence for hyperpolarisation of the vascular smooth muscle cells.
In conclusion, chronic RAAS-blockade with ACE inhibition (lisinopril) or Ang II receptor blockade (candesartan) normalised endothelial function in our rat model of MI-induced chronic heart failure to a similar extent. This improvement includes a restoration of the NO-mediated dilation after RAASblockade in our model, suggesting an important role of oxidative stress in the relation between the RAAS and endothelial dysfunction in CHF.
